ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
ASCO 2025 – zilo-V adds a patient death to its tox tally
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Harmoni spoils Summit's pre-ASCO splash
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
ASCO 2025 – Braftovi breaks new ground
The Breakwater study hits on overall survival with "unprecedented" data.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
ASCO 2025 preview – Merus tops Bicara
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
